A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension

Cephalalgia

Volumn 19, Issue 2, 1999, Pages 95-99

  Jhee, S S ^a   Salazar, D E ^b   Ford, N F ^b   Fulmor, I E ^a   Sramek, J J ^a   Cutler, Neal R ^a,c  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c 8500 Wilshire Blvd ^*  (United States)

Author keywords

Avitriptan; Hypertension; Migraine; Sumatriptan

Indexed keywords

AVITRIPTAN; SUMATRIPTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MALE; MIGRAINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

ADULT; AGED; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; SULFONAMIDES; SUMATRIPTAN; TRYPTAMINES;

EID: 0032955527     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1999.019002095.x     Document Type: Article

References (23)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. J Am Med Assoc 1992;267:64-9
2. Kimball RW, Friedman AP, Valeejo E. Effect of serotonin in migraine subjects. Neurology 1960;10;107-11
3. Lance JW, Anthony M, Gonski AG. Serotonin, the carotid body, and cranial vessels in migraine. Arch Neurol 1967;16:553-8
4. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995;45 Suppl 7:5-8
5. Rederich G, Rapaport A, Cutler N, Hazelrigg R, Jamerson B Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995;45 Suppl 7:15-20
6. Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H. et al. Pilot study of MK-462 in migraine. Cephalalgia 1996;16:113-6
7. Toda N, Fjita Y. Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine and transmural electrical stimulation. Circ Res 1973;33:98-104
8. Lance JW, Anthony M, Hinterberger H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967;7:93-102
9. Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989;9 Suppl 9:23-33
10. Bateman DN. Sumatriptan. Lancet 1993;341:221-4
11. Cutler NR, Salazar DE, Jhee SS, Fulmor IF, Ford N, Smith RA, Sramek JJ. Pharmacokinetics and pharmacodynamics of avitriptan in migraine patients following oral administration. Headache 1998;38:446-52
12. Salazar DF., Fulmor IF, Litka PA, Cutler NR, Smith RA, Ford NF. A first antimigraine drug. BMS-180048 [Abstract]. Clin Pharmacol Ther 1996;59:195
13. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993;87:401-5
14. Freedman D, Pisani R, Purves R. Statistics. New York: W. W. Norton, 1980
15. Physician's Desk Reference. 51st ed. Montvale. Medical Economics Co. 1997
16. Montiel I, Asensio M, Diaz C, Martin R, Matias-Guiu J. The prevalence rate for cardiovascular diseases antecedents in patients with migraine. Rev Neurol 1995;23:743-8
17. Perouska SJ, Price SC, Jones KW. The comorbid association of migraine with osteoarthritis and hypertension: complement C3F and Berkson's bias. Cephalalgia 1997;17:23-6
18. Paterna S, Parrinello G, Pinto A, Arrostuto A, Cottone C, Di Silvestre G, et al. Effect of sumatriptan on facial temperature variations, blood pressure and electrocardiogram in healthy subjects and patients with migraine without aura. Clin Ther 1995;146:469-76
19. Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, et al. Initial human experience with MK-462 (rixatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol 1997;43:49-54
20. Dixon R, Gillolin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1997;43:273-81
21. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double blind, placebo-controlled, dose-range finding study. Neurology 1996;46:522-6
22. Smith DA, Cleary EW, Watkins S, Huffman CS, Dilzer SC, Lasseter KC. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. J Clin Pharmacol 1998;38:685-93
23. Yildiz O, Cicek S, Ay I, Demirkilie U, Tuncer M. Hypertension increases the contractions to sumatriptan in the human internal mammary artery. Ann Thorac Surg 1996;62:1392-5